Hypogammaglobulinemia is characterized by reduced serum immunoglobulin levels.
Secondary hypogammaglobulinemia is of considerable interest to the practicing physician …

Background Anti-CD20 agents are commonly used in MS, NMOSD, and MOGAD. Few
studies have compared strategies to address hypogammaglobulinemia. Objective To …

Background Neutropenia is an infrequent complication of treatment with CD20 depleting
agents and may require the administration of granulocyte-colony stimulating factors (G …

Background and objectives Ocrelizumab and rituximab are monoclonal antibodies targeting
the CD20 marker on B lymphocytes. The enhanced efficacy of B lymphocyte depleting …

B-cell depleting anti-CD20 monoclonal antibody therapies are being increasingly used as
long-term maintenance therapy for neuroinflammatory disease compared to many non …

Long-standing use of anti-CD20 may induce hypogammaglobulinemia in patients, likely
resulting from reduced repopulation of plasma cells from precursors and further …

Abstract Objective Monoclonal antibodies (MAbs) directed against the CD20 and CD52
antigens are used increasingly in patients with multiple sclerosis (MS). Several life …

This retrospective, single-center study aimed to characterize and compare the kinetics of B-
cell reemergence following anti-CD20 infusion (anti-CD20i) in African American (AA) and …

Methods Immunoglobulin (IgG, IgG subclasses, IgA, IgM) levels, infectious outcomes, and
IgG replacement prescriptions were reviewed for MS patients seen at a tertiary academic …

Background: In multiple sclerosis (MS), the frequency of hypogammaglobulinemia is
unknown. We aimed to evaluate the frequency of reduced immunoglobulin (Ig) …